Comment on

• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Tannock IF, et al. N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720. N Engl J Med. 2004. PMID: 15470213 Clinical Trial.
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Petrylak DP, et al. N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318. N Engl J Med. 2004. PMID: 15470214 Clinical Trial.